Aloracetam

From Wikipedia, the free encyclopedia

Aloracetam

Systematic (IUPAC) name
N-[2-(3-formyl-2,5-dimethylpyrrol-1-yl)ethyl]acetamide
Clinical data
Legal status	Unscheduled
Identifiers
CAS number	119610-26-3^Y
ATC code	None
PubChem	CID 178134
ChemSpider	155069^Y
UNII	U0RKZ75D0T^Y
ChEMBL	CHEMBL2104637
Chemical data
Formula	C₁₁H₁₆N₂O₂
Mol. mass	208.257 g/mol
SMILES CC1=CC(=C(N1CCNC(=O)C)C)C=O
InChI InChI=1S/C11H16N2O2/c1-8-6-11(7-14)9(2)13(8)5-4-12-10(3)15/h6-7H,4-5H2,1-3H3,(H,12,15)^Y Key:ZUQSGZULKDDMEW-UHFFFAOYSA-N^Y
Y (what is this?) (verify)

Aloracetam is a nootropic drug of the racetam family, developed by Aventis for the treatment of Alzheimer's disease.^[1]

References

↑ Fischer F, Matthisson M, Herrling P. List of Drugs in Development for Neurodegenerative Diseases. Neurodegenerative Diseases 2004;1:50–70.

v t e Racetams

Aloracetam Aniracetam Brivaracetam Cebaracetam Coluracetam Dimiracetam Doliracetam Dupracetam Etiracetam/Levetiracetam Fasoracetam Imuracetam Molracetam Nebracetam Nefiracetam Nicoracetam Oxiracetam Phenylpiracetam Piperacetam Piracetam Pramiracetam Rolipram Rolziracetam Seletracetam

This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.